- cafead   Sep 10, 2024 at 08:52: AM
via German pharmaceutical company Boehringer Ingelheim has reported positive outcomes from the first cohort of Beamion LUNG-1, a two-part trial analysing zongertinib for treating non-small cell lung cancer (NSCLC).
article source
article source